501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Develops Version 2.0 of THC Breath
Analyzer
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- May 11, 2020
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer
of marijuana breathalyzer devices for law enforcement and the
workplace, is pleased to report that the Company has developed a
new version of its
THC
Breath Analyzer ("THCBA") and is preparing for additional
testing
with the
device. Company engineers
have updated several components in the THCBA and
have
changed
the form factor for improved
handling. Cannabix
Technologies is
on the
forefront in research and
development to create
point-of-care
breath
testing
technologies for
the
detection of ?9-tetrahydrocannabinol
("THC") - the psychoactive
component of marijuana that causes impairment. The THCBA
incorporates
microfluidic sensor technology for the detection of
THC
from
breath. New pictures of the
THCBA version 2.0 advanced prototype device are available on the
Company's website (www.cannabixtechnologies.com)
and
included in this news release.
The THCBA
has attractive features such as single-hand ergonomic
design and single-stage
direct
breath capability. Testing to date, has
shown from the time of sample
intake, the device can provide results in under 5
minutes.
The THCBA uses
a
disposable spit trap and provides easy to understand screen prompts
for the positive and negative
detection of THC in breath. Studies¹
have
shown that breath is a better
indicator of impairment than saliva, blood, or urine because
THC is present in
breath
for a relatively
short
period of time (1-3
hours); whereas,
it
is
excreted at detectable
levels in other body fluids
for many hours, days, or even weeks after smoking. This short time
period of detection in breath aligns with the peak impairment
window. The Company has been
developing the THCBA with Dr. Mina
Hoorfar
at
University of British
Columbia ("UBC") and
has an
exclusive
technology
license
agreement with
UBC.
In the
immediate term, Cannabix scientists will be testing the THCBA 2.0
device with cannabis smokers in order to (a) have more cannabis
user data to enhance the device's machine learning database and (b)
for continuous improvement purposes. It should be noted that
testing with cannabis smokers under general COVID-19 restrictions
in place has become more time-consuming as device sterilization and
organizing multi-subject testing has become more onerous. In the
THCBA 2.0 version, several components have been built using 3D
printed
technology
for rapid prototyping and design flexibility, and engineers have
begun experimenting with different materials and coatings that
would be more advantageous in manufacturing processes.
Since early March, our discussions with potential pilot/test-user
groups were paused due to the COVID-19 pandemic, however the
Company is pleased to report it is having renewed discussions with
pilot-use cases and is actively navigating how such studies will be
done with enhanced safety in mind.
Rav
Mlait, CEO, stated, "Our team have
been
diligently
pressing
forward with development of our marijuana breathalyzer devices
through the various constraints that the COVID-19 pandemic has
presented us and our suppliers. We have improved the design and
form factor of the THCBA and look forward to collecting
more
user data."
"We are
pleased to be continuing our collaborative
research efforts
with
Cannabix towards the
development of this technology under these
challenging
circumstances," stated Dr.
Hoorfar.
The
Company reports it is
granting 1,790,000
incentive
stock options exercisable at $0.50
cents per
share for five years to officers, directors and two years for
consultants.
(1) Olla
P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma
Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in
Medical Cannabis Patients. Cannabis and Cannabinoid Res.;
99-104.
Himes S.
et al. 2013. Cannabinoids in Exhaled Breath following Controlled
Administration of Smoked Cannabis. Clinical Chemistry;
1780–1789.
Beck O,
Sandqvist S, Dubbelboer I, Franck J. 2011. Detection of
delta9-tetrahydrocannabinol in exhaled breath collected from
cannabis users. J Anal Toxicol; 35:541– 4.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable tools to market to enhance detection of marijuana impaired
driving offences on roads at a time when marijuana is becoming
legal in many global jurisdictions. Cannabix is working to develop
drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular, Cannabix is focused on developing breath
testing devices for detection of recent use of THC, in contrast to
urine testing for THC metabolite that requires an invasive
collection and reflects usage, days or even weeks earlier. The
devices will also be useful for other practical applications such
as testing employees in the workplace where impairment by THC can
be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.